Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer

EGFR-TKI treatment was associated with changes in the TME of <i>EGFR</i>-mutated NSCLC, and such changes may provide clues for optimization of subsequent PD-1 inhibitor treatment.